Pluristem Therapeutics Inc. Stock Nasdaq
Equities
US72940R1023
Biotechnology & Medical Research
Sales 2022 | 234K 320K | Sales 2023 | 287K 392K | Capitalization | 32.98M 45.09M |
---|---|---|---|---|---|
Net income 2022 | -41M -56.05M | Net income 2023 | -28M -38.28M | EV / Sales 2022 | 58 x |
Net cash position 2022 | 26.21M 35.84M | Net cash position 2023 | 10.27M 14.03M | EV / Sales 2023 | 79.1 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-1.04
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.02% |
Managers | Title | Age | Since |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 53 | 06-10-31 |
Director of Finance/CFO | 40 | 13-04-30 | |
Zami Aberman
CHM | Chairman | 70 | 05-09-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 21-07-14 | |
Zami Aberman
CHM | Chairman | 70 | 05-09-25 |
Yaky Yanay
CEO | Chief Executive Officer | 53 | 06-10-31 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |